New hope for cervical cancer: drug combo targets tumors resistant to immunotherapy
NCT ID NCT05824468
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of two drugs—zimberelimab (an immunotherapy) and lenvatinib (a targeted therapy)—in 30 patients with advanced cervical cancer that has worsened after prior immunotherapy. The goal is to see if the combo can shrink tumors or slow disease progression. Researchers are also checking safety and the best dose of lenvatinib.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zimberelimab (an immunotherapy drug) and lenvatinib (a targeted therapy drug)
What this could lead to
If successful, this combination could offer a new treatment option for advanced cervical cancer patients whose disease has worsened after prior immunotherapy.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply broadly. The combination may cause significant side effects and may not improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Cetntre
Guangzhou, 510060, China